The Infant Formula Made in America Act of 2025 is a proposed law aimed at boosting the production of infant formula within the United States. By offering tax credits to smaller manufacturers, this bill seeks to prevent future shortages and ensure a steady supply of formula for American families.
What This Bill Does
The Infant Formula Made in America Act introduces two new tax credits to encourage the production of infant formula in the U.S. The first is the Domestic Infant Formula Manufacturing Investment Credit. This allows companies with global revenues under $750 million to claim a 30% tax credit on investments in equipment for manufacturing infant formula. However, these companies must ensure that at least half of their production is for U.S. use. The total amount of credits available is capped at $750 million, and no single project can receive more than $150 million. These credits can be transferred or redeemed for cash, but there are penalties if companies do not comply with the rules.
The second credit is the Infant Formula Production Credit, which gives manufacturers $2 for every pound of formula sold for U.S. use, up to 18 million pounds per year. This credit is only available to companies that have not claimed it in the previous five years, encouraging new production. Like the first credit, this one is also transferable.
The bill also includes additional rules to ensure transparency and accountability. The Treasury Department is required to issue regulations, review the credits every four years, and make public the allocations of these credits. The provisions of the bill apply to projects that begin construction after the bill is enacted.
Why It Matters
This bill is important because it addresses the risk of infant formula shortages, which can have serious consequences for families. In 2022, a recall at a major manufacturing plant led to a significant shortage, leaving many parents scrambling to find formula for their babies. By encouraging more domestic production, this bill aims to prevent similar situations in the future.
The bill benefits smaller manufacturers by lowering the barriers to entry in the infant formula market. This could lead to more competition and innovation, ultimately providing more options for parents. Additionally, by boosting domestic production, the bill enhances national food security and reduces reliance on foreign suppliers.
Key Facts
- Cost/Budget Impact: The bill provides up to $750 million in investment credits, plus production credits of $2 per pound up to 18 million pounds per year per firm.
- Timeline for Implementation: The bill applies to projects starting construction after its enactment, with regulations to be issued by the Treasury.
- Number of People Affected: The bill aims to benefit millions of families who rely on infant formula.
- Key Dates: Introduced on March 10, 2025, and currently referred to the House Ways and Means Committee.
- Bipartisan Support: The bill has sponsors from both major political parties, reflecting a shared concern over past shortages.
- No Amendments Yet: As of now, there are no proposed amendments to the bill.
- Real-World Precedent: The 2022 infant formula shortage serves as a direct precedent, highlighting the need for such legislation.
Arguments in Support
- Diversifies Supply Chain: Supporters argue that the bill will reduce the risk of shortages by increasing the number of domestic producers.
- Lowers Barriers for New Manufacturers: The tax credits make it easier for smaller companies to enter the market and compete.
- Enhances National Food Security: By increasing domestic production, the bill ensures a reliable supply of infant formula.
- Boosts Economy and Jobs: The bill is expected to create jobs in the manufacturing sector as companies expand their operations.
- Ensures Transparency: Public disclosure and regular reviews of the credits ensure accountability and taxpayer value.
Arguments in Opposition
- Fiscal Cost Concerns: Critics worry about the potential strain on the budget if the expected production does not materialize.
- Favors Specific Firms: There is concern that the bill may disproportionately benefit certain companies, potentially distorting the market.
- Complexity and Bureaucracy: The process of obtaining certification and complying with regulations may be burdensome for companies.
- Doesn't Address Root Issues: Some argue that the bill does not tackle the underlying regulatory barriers that prevent new entrants.